AF's-affiliated website thinks a failed clinical trial was a "valiant attempt" even though the (smaller company's) drug utterly failed.

https://www.fiercebiotech.com/biotech/synapto...hare-value

But when AVXL has a successful clinical trial, he attacks the company for supposedly cherry-picking results (AKA doing an in-depth analysis).

I guess it depends on which stock you're pumping, and which stock you're shorting.